GPCR: Structure Therapeutics Inc - American Depositary Shares

GPCR Haberleri

• 13:51 Does EU Approval of Wegovy Pill Change NVO's Competitive Story?
• 14:11 NVO Rallies 11% in a Month: How Should Investors Play the Stock?
• 12:46 Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry (NYSE:NVO)
• 14:10 LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?
• 13:12 Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
• 12:49 Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• 14:22 Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
• 14:01 Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?
• 14:40 Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
• 17:03 Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade) (GPCR)
• 11:32 H.C. Wainwright, Structure Therapeutics hisse hedefini 70 dolara düşürdü
• 18:32 Oral GLP-1 obezite ilaçları hızlı benimseniyor
• 14:54 Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?
• 13:36 Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?
• 18:53 Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.
• 13:34 Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
• 12:56 LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?
• 11:19 GLP-1 Sales Forecast Jumps To $150 Billion By 2030
• 14:49 LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
• 14:14 Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
• 14:34 LLY Reports Third Phase III Win for Next-Generation Obesity Drug
• 15:35 Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
• 14:20 Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
• 15:47 Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead